C

China Shineway Pharmaceutical Group Ltd
HKEX:2877

Watchlist Manager
China Shineway Pharmaceutical Group Ltd
HKEX:2877
Watchlist
Price: 7.8 HKD 0.78% Market Closed
Market Cap: 6.5B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
China Shineway Pharmaceutical Group Ltd

Wall Street analysts forecast China Shineway Pharmaceutical Group Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for China Shineway Pharmaceutical Group Ltd is 12.41 HKD with a low forecast of 8.59 HKD and a high forecast of 18.9 HKD.

Lowest Forecast
Wall Street Target
8.59 HKD
10% Upside
Average Forecast
Wall Street Target
12.41 HKD
59% Upside
Highest Forecast
Wall Street Target
18.9 HKD
142% Upside
Lowest
Price Target
8.59 HKD
10% Upside
Average
Price Target
12.41 HKD
59% Upside
Highest
Price Target
18.9 HKD
142% Upside
China Shineway Pharmaceutical Group Ltd Competitors:
Price Targets
4554
Fuji Pharma Co Ltd
55% Upside
600332
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
2% Upside
D
DHG
Dhg Pharmaceutical Joint-Stock Co
12% Upside
ELAN
Elanco Animal Health Inc
6% Upside
4554
Fuji Pharma Co Ltd
55% Upside
600332
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
2% Upside
D
DHG
Dhg Pharmaceutical Joint-Stock Co
12% Upside
ELAN
Elanco Animal Health Inc
6% Upside
OGI
OrganiGram Holdings Inc
50% Upside
C
6919
Caliway Biopharmaceuticals Co Ltd
18% Upside
4506
Sumitomo Pharma Co Ltd
19% Downside

Revenue
Forecast

Revenue Estimate
China Shineway Pharmaceutical Group Ltd

For the last 8 years the compound annual growth rate for China Shineway Pharmaceutical Group Ltd's revenue is 8%. The projected CAGR for the next 3 years is 6%.

8%
Past Growth
6%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
China Shineway Pharmaceutical Group Ltd

For the last 8 years the compound annual growth rate for China Shineway Pharmaceutical Group Ltd's operating income is 7%. The projected CAGR for the next 3 years is 10%.

7%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
China Shineway Pharmaceutical Group Ltd

For the last 8 years the compound annual growth rate for China Shineway Pharmaceutical Group Ltd's net income is 5%. The projected CAGR for the next 2 years is 23%.

5%
Past Growth
23%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is China Shineway Pharmaceutical Group Ltd's stock price target?
Price Target
12.41 HKD

According to Wall Street analysts, the average 1-year price target for China Shineway Pharmaceutical Group Ltd is 12.41 HKD with a low forecast of 8.59 HKD and a high forecast of 18.9 HKD.

What is China Shineway Pharmaceutical Group Ltd's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for China Shineway Pharmaceutical Group Ltd's revenue is 8%. The projected CAGR for the next 3 years is 6%.

What is China Shineway Pharmaceutical Group Ltd's Operating Income forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for China Shineway Pharmaceutical Group Ltd's operating income is 7%. The projected CAGR for the next 3 years is 10%.

What is China Shineway Pharmaceutical Group Ltd's Net Income forecast?
Projected CAGR
23%

For the last 8 years the compound annual growth rate for China Shineway Pharmaceutical Group Ltd's net income is 5%. The projected CAGR for the next 2 years is 23%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 264,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.